![]() | |
Clinical data | |
---|---|
Other names | TAK-013 |
Routes of administration | By mouth |
Drug class | GnRH modulator; GnRH antagonist; Antigonadotropin |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C36H31F2N5O4S |
Molar mass | 667.73 g·mol−1 |
3D model ( JSmol) | |
| |
|
Sufugolix ( INN , BAN ) (developmental code name TAK-013) is a non-peptide, orally-active, selective antagonist of the gonadotropin-releasing hormone receptor (GnRHR) ( IC50 = 0.1 and 0.06 nM for affinity and in vitro inhibition, respectively). [1] It was under development by Takeda for the treatment of endometriosis and uterine leiomyoma and reached phase II clinical trials for both of these indications, but was subsequently discontinued. [2] [3] It seems to have been supplanted by relugolix (TAK-385), which is also under development by Takeda for the treatment of these conditions and has a more favorable drug profile (including reduced cytochrome P450 inhibition and improved in vivo GnRHR antagonistic activity) in comparison. [4]
Oral administration of sufugolix at a dose of 30 mg/kg to castrated male cynomolgus monkeys resulted in nearly complete suppression of luteinizing hormone levels. [1] The duration of action was more than 24 hours, indicating a long elimination half-life of the drug. [1] The suppressive effects of sufugolix on gonadotropin and sex hormone levels are rapidly reversible with discontinuation. [5]
Unlike various other GnRHR antagonists, sufugolix has been elucidated to be a non-competitive or insurmountable/trapping antagonist of the GnRHR rather than a competitive antagonist. [6] [7]
![]() | |
Clinical data | |
---|---|
Other names | TAK-013 |
Routes of administration | By mouth |
Drug class | GnRH modulator; GnRH antagonist; Antigonadotropin |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C36H31F2N5O4S |
Molar mass | 667.73 g·mol−1 |
3D model ( JSmol) | |
| |
|
Sufugolix ( INN , BAN ) (developmental code name TAK-013) is a non-peptide, orally-active, selective antagonist of the gonadotropin-releasing hormone receptor (GnRHR) ( IC50 = 0.1 and 0.06 nM for affinity and in vitro inhibition, respectively). [1] It was under development by Takeda for the treatment of endometriosis and uterine leiomyoma and reached phase II clinical trials for both of these indications, but was subsequently discontinued. [2] [3] It seems to have been supplanted by relugolix (TAK-385), which is also under development by Takeda for the treatment of these conditions and has a more favorable drug profile (including reduced cytochrome P450 inhibition and improved in vivo GnRHR antagonistic activity) in comparison. [4]
Oral administration of sufugolix at a dose of 30 mg/kg to castrated male cynomolgus monkeys resulted in nearly complete suppression of luteinizing hormone levels. [1] The duration of action was more than 24 hours, indicating a long elimination half-life of the drug. [1] The suppressive effects of sufugolix on gonadotropin and sex hormone levels are rapidly reversible with discontinuation. [5]
Unlike various other GnRHR antagonists, sufugolix has been elucidated to be a non-competitive or insurmountable/trapping antagonist of the GnRHR rather than a competitive antagonist. [6] [7]